Cellular Origins

Cellular Origins Ltd, founded in 2022, is based in Melbourn, UK, and is dedicated to developing cutting-edge solutions for cell therapy manufacturing.Cellular Origins specializes in the development and commercialization of its flagship product, the Constellation® ecosystem, a mobile robotic automation platform tailored specifically for the cell therapy manufacturing sector. This advanced platform integrates robotics and automation to streamline existing cell therapy processes, offering clients a fully automated, GMP-compliant solution that enhances efficiency, precision, and flexibility. Constellation enables therapy developers to scale their processes without significant alterations to their existing workflows, which is crucial for responding to the growing demand for cell therapies. The company's client base primarily includes biopharmaceutical companies engaged in the development and manufacturing of autologous and allogeneic cell therapies, particularly in regions such as North America, Europe, and parts of Asia. The company operates primarily on a B2B model, engaging directly with biopharmaceutical manufacturers who utilize the Constellation platform for their production needs. Revenue generation occurs through partnerships and collaborations with clients, providing tailored automation solutions that integrate seamlessly with their existing manufacturing processes. The pricing structure for Constellation and associated services is designed to accommodate varying scales of operation, allowing clients to choose options that best suit their production needs and growth trajectories. The company plans to introduce new product offerings that enhance the existing Constellation platform, although specific release dates are not yet disclosed. Cellular Origins also targets expansion into new geographic markets, particularly in North America and Asia, by the end of 2026, to meet the growing demands of the cell therapy sector.

1. Series A

   Nov 24, 2025

   Amount

   $40M

   Investors

   Locked